Update on the treatment of disseminated fusariosis: Focus on voriconazole

Therapeutics and Clinical Risk Management

Volumn 3, Issue 6, 2007, Pages 1165-1173

  Stanzani, Marta ^a   Tumietto, Fabio ^a   Vianelli, Nicola ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aspergillus; Cancer; Fungal infections; Fusariosis; Immunocompromised patient; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; NATAMYCIN; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; STEROID; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASPERGILLOSIS; CRITICALLY ILL PATIENT; CRYPTOCOCCOSIS; DERMATOMYCOSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EYE INFECTION; FUSARIOSIS; FUSARIUM; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; KERATITIS; LIVER ABSCESS; LIVER DYSFUNCTION; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PERITONITIS; PNEUMONIA; REVIEW; SOFT TISSUE INFECTION; VISUAL DISORDER;

EID: 38049153781     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Al-Abdely HM. 2004. Management of rare fungal infections. Curr Opin Infect Dis, 17:527-32.
2. Alkan Y, Haefeli WE, Burhenne J, et al. 2004. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis, 39:e49-52.
3. Alvarez-Lerma F, Nicolas-Arfelis JM, Rodriguez-Borregan JC, et al. 2005. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother, 17:417-27.
4. Anaissie E, Kantarjian H, Jones P, et al. 1986. Fusarium. A newly recognized fungal pathogen in immunosuppressed patients. Cancer, 57:2141-5.
5. Anandi V, Vishwanathan P, Sasikala S, et al. 2005. Fusarium solani breast abscess. Indian J Med Microbiology, 23:198-9.
6. Apostolidis J, Bouzani M, Platsouka E, et al. 2003. Resolution of fungemia due to Fusarium spp. in a patient with acute leukemia treated with caspofungin. Clin Infect Dis, 36:1349-50.
7. Arikan S, Lozano-Chiu M, Paetznick V, et al. 1999. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol, 37:3946-51.
8. Austen B, McCarthy H, Wilkins B, et al. 2001. Fatal disseminated Fusarium infection in acute lymphoblastic leukemia in complete remission. J Clin Pathol, 54:488-90.
9. Bigley VH, Duarte RF, Gosling RD, et al. 2004. Fusarium dimerum infection in a stem cell transplant recipient treated successfully with voriconazole. Bone Marrow Transplant, 34:815-17.
10. Bodey GP, Boktour M, Mays S, et al. 2002. Skin lesions associated with Fusarium infection. J Am Acad Dermatol, 47:659-66.
11. Boutati E, Anaissie EJ. 1997. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood, 90:999-1008.
12. Bunya VY, Hammersmith KM, Rapuano CJ, et al. 2007. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol, 143:151-3.
13. Charvalos E, Tsatsakis A, Tzatzarakis M, et al. 2002. New nystatin polymeric complexes and their in vitro antifungal evaluation in a model study with Fusarium oxysporum. Mycopathologia, 153:15-19.
14. Cocuroccia B, Gaido J, Gubinelli E, et al. 2003. Localized cutaneous hyalohyphomycosis caused by Fusarium spp. infection in a renal transplant patient. J Clin Microbiology, 41:905-7.
15. Consigny S, Dhedin N, Datry A, et al. 2003. Successful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin Infect Dis, 37:311-13.
16. Cudillo L, Girmenia C, Santilli S, et al. 2005. Brekthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin Infect Dis, 40:1212-13.
17. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother, 50:917-21.
18. Denning DW, Ribaud P, Milpied N, et al. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis, 34:563-71.
19. Denning DW, Kibbler CC, Barnes RA, et al. 2003. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis, 3:230-40.
20. Dismukes WE. 2000. Introduction to antifungal drugs. Clin Infect Dis, 30:653-7.
21. Durand ML, Kim IK, D'Amico DJ, et al. 2005. Successful treatment of Fusarium endophtalmitis with voriconazole and Aspergillus endophtalmitis with voriconazole plus caspofungin. Am J Ophtalmology, 140:552-4.
22. Espinel-Ingroff A. 1998. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol, 36:2950-6.
23. Espinel-Ingroff A, Fothergill A, Ghannoum M, et al. 2005. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38-A Document) for amphotericin B, itraconazole, posaconazole and voriconazole. J Clini Microbiol, 43:5243-6.
24. European Agency for the Evaluation of Medical Products. 2007. VFEND: summary of product characteristics [online]. URL: http://www.emea.eu.int.
25. Garbino J, Uckay I, Rohner P, et al. 2005. Fusarium peritonitis concomitant to kidney transplantation successfully managed with voriconazole: case report and review of the literature. Transpl Int, 18:613-18.
26. Ghannoum MA, Kuhn DM. 2002. Voriconazole-better chances for patients with invasive mycoses. Eur J Med Res, 7:242-56.
27. Giaconi JA, Marangon FB, Miller D, et al. 2006. Voriconazole and fungal keratitis: a report of two treatment failures. J Ocul Pharmacol Ther, 22:437-9.
28. Gorman SR, Magiorakos AP, Zimmerman SK, et al. 2006. Fusarium oxysporum pneumonia in an immunocompetent host. South Med J, 99:613-16.
29. Guarro J, Gene J. 1995. Opportunistic fusarial infections in humans. Eur J Clin Microbiol Infect Dis, 14:741-54.
30. Guimerá-Martín-Neda F, García-Bustinduy M, Noda-Cabrera A, et al. 2004. Cutaneous infection by Fusarium: successful treatment with oral voriconazole. British J Dermatol, 150:770-95.
31. Guzman-Cottrill JA, Zheng Xiaotian, Chadwick EG. 2004. Fusarium solani endocarditis successfully treated with liposomial amphotericin B and voriconazole. Pediatric Infect Dis J, 23:1059-60.
32. Hamaki T, Kami M, Kishi A, et al. 2004. Vesicles as initial skin manifestation of disseminated fusariosis after non-myeloablative stem cell transplantation. Leuk Lymphoma, 45:631-3.
33. Herbrecht R, Denning DW, Patterson TF, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347:408-15.
34. Herbrecht R. 2004. Voriconazole: therapeutic review of a new azole anti-fungal. Expert Rev Anti Infect Ther, 2:485-97.
35. Herbrecht R, Kessler R, Kravanja C, et al. 2004. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant, 23:1451-4.
36. Heyn K, Tredup A, Salvenmoser S, et al. 2005. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. J Antimicrob Chemother, 49:5157-9.
37. Hsu CK, Hsu MM, Lee JY. 2006. Fusariosis occurring in an ulcerated cutaneous CD8+ T cell lymphoma tumor. Eur J Dermatol, 16:297-301.
38. Jensen TG, Gahrn-Hansen B, Arendrup M, et al. 2004. Fusarium fungemia in immunocompromised patients. Clin Microbiol Infect, 10:499-501.
39. Johnson EM, Szekely A, Warnock DW. 1998. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother, 42:741-5.
40. Johnson LB, Kauffman CA. 2003. Voriconazole: a new triazole antifungal agent. Clin Infect Dis, 36:630-7.
41. Khoury H, Ball NJ. 2003. Disseminated fusariosis in a patient with acute leukemia. Br J Haematol, 120:1.
42. Kivivouri SM, Hovi L, Vetternanta K, et al. 2004. Invasive fusariosis in two transplanted children. Eur J Pediatr, 163:692-3.
43. Kontoyiannis DP, Bodey GP, Hanna H, et al. 2004. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma, 45:139-41.
44. Krcmery V Jr, Jesenska Z, Spanik S, et al. 1997. Fungaemia due to Fusarium spp. in cancer patients. J Hosp Infect, 36:223-8.
45. Lewis R, Wiederhold NP, Klepser ME. 2005. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium and Scedosporium spp. Antimicrob Agents Chemother, 49:945-51.
46. Lin HC, Chu PH, Kuo YH, et al. 2005. Clinical experience in managing Fusarium solani keratitis. Int Clin Pract, 59:549-54.
47. Linares MJ, Charriel G, Solls F, et al. 2005. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods. J ClinMicrobiol, 43:250-3.
48. Linden P, Williams P, Chan KM. 2000. Efficacy and safety of amphotericine B lipid complex injection (ABLC) in solid organ transplant recipients with invasive fungal infection. Clin Transpl, 14:329-39.
49. Lodato F, Tamé MR, Montagnani M, et al. 2006. Systemic fungemia and hepatic localization of Fusarium solani in a liver transplanted patient: an emerging fungal agent. Liver Transpl, 12:1711-14.
50. Madariaga MG, Kohl S. 2006. Disseminated fusariosis presenting with pulmonary nodules following a line infection. Braz J Infect Diseases, 10:426.
51. Marco F, Pfaller MA, Messer SA, et al. 1998. Antifungal activity of a new triazole, voniconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol, 36:433-6.
52. Marr KA, Carter RA, Crippa F, et al. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis, 34:909-17.
53. Mouas H, Lutsar I, Dupont B, et al. 2005. Voniconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis, 40:1141-47.
54. Musa MO, Al Eisa A, Halim M, et al. 2000. The spectrum of Fusarium infection in immunocompromised patients with hematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br J Haematol, 108:544-8.
55. Nelson PE, Dignani MC, Anaissie EJ. 1994. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev, 7:479-504.
56. Nucci M, Anaissie EJ. 2002. Cutaneous infection by Fusarium species in healthy and immunocompromised host: implication for diagnosis and management. Clin Infect Dis, 35:909-20.
57. Nucci M. 2003. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis, 16:607-12.
58. Nucci M, Anaissie EJ, Queiroz-Telles F, et al. 2003. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer, 98:315-19.
59. Nucci M, Marr KA, Queiroz-Telles F, et al. 2004. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis, 38:1237-42.
60. Oliveira JS, Klerbauy FR, Colombo AL, et al. 2002. Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole. Braz J Med Biol Res, 35:789-98.
61. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. 2002. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother, 46:3298-300.
62. Pereiro M Jr, Abalde MT, Zulaica A, et al. 2001. Chronic infection due to Fusarium oxysporum mimicking lupus vulgaris: case report and review of cutaneous involvement in fusariosis. Acta Derm Venereol, 81:51-3.
63. Perfect JR, Marr KA, Walsh TJ, et al. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis, 36:1122-31.
64. Pfaller MA, Marco F, Messer SA, et al. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis, 30:251-5.
65. Pfaller MA, Messer SA, Mills K, et al. 2000. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol, 38:3359-61.
66. Pfaller MA, Messer SA, Hollis RJ, et al. 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother, 46:1032-7.
67. Philip A, Odabasi Z, Rodriguez J, et al. 2005. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother, 49:3572-4.
68. Polizzi A, Siniscalchi C, Mastromarino A, et al. 2004. Effect of voriconazole on a corneal abscess caused by Fusarium. Acta Ophtalmol Scand, 82:762-4.
69. Potoski BA, Brown J. 2002. The safety of voriconazole. Clin Infect Dis, 34:563-71.
70. Raad I, Hachem RY, Herbrecht R, et al. 2006. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematological malignancies and other conditions. Clin Infect Dis, 42:1398-403.
71. Reis A, Sundmacher R, Tintelnot K, et al. 2000. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol, 84:932-33.
72. Rodriguez CA, Luján-Zilbermann J, Wooderd P. 2003. Successful treatment of disseminated fusariosis. Bone Marrow Transpl, 31:411-12.
73. Sagnelli C, Fumagalli L, Prigitano A, et al. 2006. Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. J Antimicrob Chemother, 57:796-8.
74. Sampathkumar P, Paya CV. 2001. Fusarium infection after solid organ transplant. Clin Infect Dis, 32:1237-40.
75. Scott LJ, Simpson D. 2007. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs, 67:269-98.
76. Selleslag D. 2006. A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. Acta Biomed, 77(Suppl 2):32-5.
77. Singh N. 2003. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis, 3:156-61.
78. Spellberg B, Schwartz J, Fu Y, et al. 2006. Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother, 58:973-9.
79. Sponsel WE, Graybill JR, Nevarez HL, et al. 2002. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol, 86:829-30.
80. Stanzani M, Vianelli N, Bandini G, et al. 2006. Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomial amphotericin. B J Infect, 53:e243-6.
81. Teixeira AB, Silva M, Lyra L, et al. 2005. Antifungal susceptibility and pathogenic potential of environmental isolated filamentous fungi compared with colonizing agents in immunocompromised patients. Mycopathologia, 160:129-35.
82. Tones HA, Hachem RY, Chemaly RF, et al. 2005. Posaconazole: a broad-spectrum tiazole antifungal. Lancet Infect Dis, 5:775-85.
83. Tu EY, McCartney DL, Beatty RF, et al. 2007. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophtalmol, 143:222-7.
84. Vincent AL, Cabrero JE, Greene JN, et al. 2003. Successful voriconazole therapy of disseminated Fusarium solani in the brain of a neutropenic cancer patient. Cancer Control, 10:414-19.
85. Walsh TJ, Groll A, Hiemenz J, et al. 2004. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect, 10(Suppl 1):48-66.
86. Young CN, Meyers AM. 1979. Opportunistic fungal infection by Fusarium oxysporum in a renal transplant patient. Sabouraudia, 17:219-23.